Dystrophin is a tumor suppressor in human cancers with myogenic programs

Yuexiang Wang, Adrian Marino-Enriquez, Richard R. Bennett, Meijun Zhu, Yiping Shen, Grant Eilers, Jen Chieh Lee, Joern Henze, Benjamin S. Fletcher, Zhizhan Gu, Edward A. Fox, Cristina R. Antonescu, Christopher D M Fletcher, Xiangqian Guo, Chandrajit P. Raut, George D. Demetri, Matt Van De Rijn, Tamas Ordog, Louis M. Kunkel, Jonathan A. Fletcher

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Many common human mesenchymal tumors, including gastrointestinal stromal tumor (GIST), rhabdomyosarcoma (RMS) and leiomyosarcoma (LMS), feature myogenic differentiation. Here we report that intragenic deletion of the dystrophin-encoding and muscular dystrophy-associated DMD gene is a frequent mechanism by which myogenic tumors progress to high-grade, lethal sarcomas. Dystrophin is expressed in the non-neoplastic and benign counterparts of GIST, RMS and LMS tumors, and DMD deletions inactivate larger dystrophin isoforms, including 427-kDa dystrophin, while preserving the expression of an essential 71-kDa isoform. Dystrophin inhibits myogenic sarcoma cell migration, invasion, anchorage independence and invadopodia formation, and dystrophin inactivation was found in 96%, 100% and 62% of metastatic GIST, embryonal RMS and LMS samples, respectively. These findings validate dystrophin as a tumor suppressor and likely anti-metastatic factor, suggesting that therapies in development for muscular dystrophies may also have relevance in the treatment of cancer.

Original languageEnglish (US)
Pages (from-to)601-606
Number of pages6
JournalNature Genetics
Volume46
Issue number6
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Dystrophin
Gastrointestinal Stromal Tumors
Leiomyosarcoma
Neoplasms
Rhabdomyosarcoma
Muscular Dystrophies
Sarcoma
Protein Isoforms
Embryonal Rhabdomyosarcoma
Cell Movement
Genes

ASJC Scopus subject areas

  • Genetics

Cite this

Wang, Y., Marino-Enriquez, A., Bennett, R. R., Zhu, M., Shen, Y., Eilers, G., ... Fletcher, J. A. (2014). Dystrophin is a tumor suppressor in human cancers with myogenic programs. Nature Genetics, 46(6), 601-606. https://doi.org/10.1038/ng.2974

Dystrophin is a tumor suppressor in human cancers with myogenic programs. / Wang, Yuexiang; Marino-Enriquez, Adrian; Bennett, Richard R.; Zhu, Meijun; Shen, Yiping; Eilers, Grant; Lee, Jen Chieh; Henze, Joern; Fletcher, Benjamin S.; Gu, Zhizhan; Fox, Edward A.; Antonescu, Cristina R.; Fletcher, Christopher D M; Guo, Xiangqian; Raut, Chandrajit P.; Demetri, George D.; Van De Rijn, Matt; Ordog, Tamas; Kunkel, Louis M.; Fletcher, Jonathan A.

In: Nature Genetics, Vol. 46, No. 6, 2014, p. 601-606.

Research output: Contribution to journalArticle

Wang, Y, Marino-Enriquez, A, Bennett, RR, Zhu, M, Shen, Y, Eilers, G, Lee, JC, Henze, J, Fletcher, BS, Gu, Z, Fox, EA, Antonescu, CR, Fletcher, CDM, Guo, X, Raut, CP, Demetri, GD, Van De Rijn, M, Ordog, T, Kunkel, LM & Fletcher, JA 2014, 'Dystrophin is a tumor suppressor in human cancers with myogenic programs', Nature Genetics, vol. 46, no. 6, pp. 601-606. https://doi.org/10.1038/ng.2974
Wang Y, Marino-Enriquez A, Bennett RR, Zhu M, Shen Y, Eilers G et al. Dystrophin is a tumor suppressor in human cancers with myogenic programs. Nature Genetics. 2014;46(6):601-606. https://doi.org/10.1038/ng.2974
Wang, Yuexiang ; Marino-Enriquez, Adrian ; Bennett, Richard R. ; Zhu, Meijun ; Shen, Yiping ; Eilers, Grant ; Lee, Jen Chieh ; Henze, Joern ; Fletcher, Benjamin S. ; Gu, Zhizhan ; Fox, Edward A. ; Antonescu, Cristina R. ; Fletcher, Christopher D M ; Guo, Xiangqian ; Raut, Chandrajit P. ; Demetri, George D. ; Van De Rijn, Matt ; Ordog, Tamas ; Kunkel, Louis M. ; Fletcher, Jonathan A. / Dystrophin is a tumor suppressor in human cancers with myogenic programs. In: Nature Genetics. 2014 ; Vol. 46, No. 6. pp. 601-606.
@article{008725948c4a4ccfbbfdff6605c21930,
title = "Dystrophin is a tumor suppressor in human cancers with myogenic programs",
abstract = "Many common human mesenchymal tumors, including gastrointestinal stromal tumor (GIST), rhabdomyosarcoma (RMS) and leiomyosarcoma (LMS), feature myogenic differentiation. Here we report that intragenic deletion of the dystrophin-encoding and muscular dystrophy-associated DMD gene is a frequent mechanism by which myogenic tumors progress to high-grade, lethal sarcomas. Dystrophin is expressed in the non-neoplastic and benign counterparts of GIST, RMS and LMS tumors, and DMD deletions inactivate larger dystrophin isoforms, including 427-kDa dystrophin, while preserving the expression of an essential 71-kDa isoform. Dystrophin inhibits myogenic sarcoma cell migration, invasion, anchorage independence and invadopodia formation, and dystrophin inactivation was found in 96{\%}, 100{\%} and 62{\%} of metastatic GIST, embryonal RMS and LMS samples, respectively. These findings validate dystrophin as a tumor suppressor and likely anti-metastatic factor, suggesting that therapies in development for muscular dystrophies may also have relevance in the treatment of cancer.",
author = "Yuexiang Wang and Adrian Marino-Enriquez and Bennett, {Richard R.} and Meijun Zhu and Yiping Shen and Grant Eilers and Lee, {Jen Chieh} and Joern Henze and Fletcher, {Benjamin S.} and Zhizhan Gu and Fox, {Edward A.} and Antonescu, {Cristina R.} and Fletcher, {Christopher D M} and Xiangqian Guo and Raut, {Chandrajit P.} and Demetri, {George D.} and {Van De Rijn}, Matt and Tamas Ordog and Kunkel, {Louis M.} and Fletcher, {Jonathan A.}",
year = "2014",
doi = "10.1038/ng.2974",
language = "English (US)",
volume = "46",
pages = "601--606",
journal = "Nature Genetics",
issn = "1061-4036",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Dystrophin is a tumor suppressor in human cancers with myogenic programs

AU - Wang, Yuexiang

AU - Marino-Enriquez, Adrian

AU - Bennett, Richard R.

AU - Zhu, Meijun

AU - Shen, Yiping

AU - Eilers, Grant

AU - Lee, Jen Chieh

AU - Henze, Joern

AU - Fletcher, Benjamin S.

AU - Gu, Zhizhan

AU - Fox, Edward A.

AU - Antonescu, Cristina R.

AU - Fletcher, Christopher D M

AU - Guo, Xiangqian

AU - Raut, Chandrajit P.

AU - Demetri, George D.

AU - Van De Rijn, Matt

AU - Ordog, Tamas

AU - Kunkel, Louis M.

AU - Fletcher, Jonathan A.

PY - 2014

Y1 - 2014

N2 - Many common human mesenchymal tumors, including gastrointestinal stromal tumor (GIST), rhabdomyosarcoma (RMS) and leiomyosarcoma (LMS), feature myogenic differentiation. Here we report that intragenic deletion of the dystrophin-encoding and muscular dystrophy-associated DMD gene is a frequent mechanism by which myogenic tumors progress to high-grade, lethal sarcomas. Dystrophin is expressed in the non-neoplastic and benign counterparts of GIST, RMS and LMS tumors, and DMD deletions inactivate larger dystrophin isoforms, including 427-kDa dystrophin, while preserving the expression of an essential 71-kDa isoform. Dystrophin inhibits myogenic sarcoma cell migration, invasion, anchorage independence and invadopodia formation, and dystrophin inactivation was found in 96%, 100% and 62% of metastatic GIST, embryonal RMS and LMS samples, respectively. These findings validate dystrophin as a tumor suppressor and likely anti-metastatic factor, suggesting that therapies in development for muscular dystrophies may also have relevance in the treatment of cancer.

AB - Many common human mesenchymal tumors, including gastrointestinal stromal tumor (GIST), rhabdomyosarcoma (RMS) and leiomyosarcoma (LMS), feature myogenic differentiation. Here we report that intragenic deletion of the dystrophin-encoding and muscular dystrophy-associated DMD gene is a frequent mechanism by which myogenic tumors progress to high-grade, lethal sarcomas. Dystrophin is expressed in the non-neoplastic and benign counterparts of GIST, RMS and LMS tumors, and DMD deletions inactivate larger dystrophin isoforms, including 427-kDa dystrophin, while preserving the expression of an essential 71-kDa isoform. Dystrophin inhibits myogenic sarcoma cell migration, invasion, anchorage independence and invadopodia formation, and dystrophin inactivation was found in 96%, 100% and 62% of metastatic GIST, embryonal RMS and LMS samples, respectively. These findings validate dystrophin as a tumor suppressor and likely anti-metastatic factor, suggesting that therapies in development for muscular dystrophies may also have relevance in the treatment of cancer.

UR - http://www.scopus.com/inward/record.url?scp=84901680208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901680208&partnerID=8YFLogxK

U2 - 10.1038/ng.2974

DO - 10.1038/ng.2974

M3 - Article

C2 - 24793134

AN - SCOPUS:84901680208

VL - 46

SP - 601

EP - 606

JO - Nature Genetics

JF - Nature Genetics

SN - 1061-4036

IS - 6

ER -